New antibody drug shows promise in slowing advanced cancers
NCT ID NCT04452955
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study tests a new drug called PRL3-zumab in adults with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug can slow tumor growth or shrink tumors. About 51 participants will receive the drug, and researchers will track how long they live without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89014, United States
-
HonorHealth Research
Scottsdale, Arizona, 85258, United States
-
Norton Healthcare
Louisville, Kentucky, 40200, United States
-
St. Jude Medical Center
Fullerton, California, 92835, United States
-
The Angeles Clinic
Los Angeles, California, 90025, United States
Conditions
Explore the condition pages connected to this study.